These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 16764999)

  • 1. Mutations induced by carcinogenic doses of aristolochic acid in kidney of Big Blue transgenic rats.
    Chen L; Mei N; Yao L; Chen T
    Toxicol Lett; 2006 Sep; 165(3):250-6. PubMed ID: 16764999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA adduct formation and mutation induction by aristolochic acid in rat kidney and liver.
    Mei N; Arlt VM; Phillips DH; Heflich RH; Chen T
    Mutat Res; 2006 Dec; 602(1-2):83-91. PubMed ID: 17010389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations induced by the carcinogenic pyrrolizidine alkaloid riddelliine in the liver cII gene of transgenic big blue rats.
    Mei N; Heflich RH; Chou MW; Chen T
    Chem Res Toxicol; 2004 Jun; 17(6):814-8. PubMed ID: 15206902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aristolochic acid-induced carcinogenesis examined by ACB-PCR quantification of H-Ras and K-Ras mutant fraction.
    Wang Y; Meng F; Arlt VM; Mei N; Chen T; Parsons BL
    Mutagenesis; 2011 Sep; 26(5):619-28. PubMed ID: 21642617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue-specific microRNA responses in rats treated with mutagenic and carcinogenic doses of aristolochic acid.
    Meng F; Li Z; Yan J; Manjanatha M; Shelton S; Yarborough S; Chen T
    Mutagenesis; 2014 Sep; 29(5):357-65. PubMed ID: 25106556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutagenicity of aristolochic acid in the lambda/lacZ transgenic mouse (MutaMouse).
    Kohara A; Suzuki T; Honma M; Ohwada T; Hayashi M
    Mutat Res; 2002 Mar; 515(1-2):63-72. PubMed ID: 11909755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acrylamide-induced carcinogenicity in mouse lung involves mutagenicity: cII gene mutations in the lung of big blue mice exposed to acrylamide and glycidamide for up to 4 weeks.
    Manjanatha MG; Guo LW; Shelton SD; Doerge DR
    Environ Mol Mutagen; 2015 Jun; 56(5):446-56. PubMed ID: 25639614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the mutagenicity of aristolochic acid I and aristolochic acid II in the gpt delta transgenic mouse kidney.
    Xing G; Qi X; Chen M; Wu Y; Yao J; Gong L; Nohmi T; Luan Y; Ren J
    Mutat Res; 2012 Mar; 743(1-2):52-8. PubMed ID: 22245565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression profiles distinguish the carcinogenic effects of aristolochic acid in target (kidney) and non-target (liver) tissues in rats.
    Chen T; Guo L; Zhang L; Shi L; Fang H; Sun Y; Fuscoe JC; Mei N
    BMC Bioinformatics; 2006 Sep; 7 Suppl 2(Suppl 2):S20. PubMed ID: 17118142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutagenicity and DNA adduct formation by aristolochic acid in the spleen of Big Blue® rats.
    McDaniel LP; Elander ER; Guo X; Chen T; Arlt VM; Mei N
    Environ Mol Mutagen; 2012 Jun; 53(5):358-68. PubMed ID: 22508110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of mutant frequencies at the transgenic lambda LacI and cII/cI loci in control and ENU-treated Big Blue mice.
    Zimmer DM; Harbach PR; Mattes WB; Aaron CS
    Environ Mol Mutagen; 1999; 33(3):249-56. PubMed ID: 10334627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the weak in vivo micronucleus response of a genotoxic carcinogen, aristolochic acids.
    Bhalli JA; Ding W; Shaddock JG; Pearce MG; Dobrovolsky VN; Heflich RH
    Mutat Res; 2013 May; 753(2):82-92. PubMed ID: 23500662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotoxicity of acrylamide and its metabolite glycidamide administered in drinking water to male and female Big Blue mice.
    Manjanatha MG; Aidoo A; Shelton SD; Bishop ME; McDaniel LP; Lyn-Cook LE; Doerge DR
    Environ Mol Mutagen; 2006 Jan; 47(1):6-17. PubMed ID: 15957192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time course of cII gene mutant manifestation in the liver, spleen, and bone marrow of N-ethyl-N-nitrosourea-treated Big Blue transgenic mice.
    Wang J; Liu X; Heflich RH; Chen T
    Toxicol Sci; 2004 Nov; 82(1):124-8. PubMed ID: 15282403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotoxicity of 1,3-butadiene and its epoxy intermediates.
    Walker VE; Walker DM; Meng Q; McDonald JD; Scott BR; Seilkop SK; Claffey DJ; Upton PB; Powley MW; Swenberg JA; Henderson RF;
    Res Rep Health Eff Inst; 2009 Aug; (144):3-79. PubMed ID: 20017413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interpretation of mutational spectra from different genes: analyses of PhIP-induced mutational specificity in the lacI and cII transgenes from colon of Big Blue rats.
    Stuart GR; Thorleifson E; Okochi E; de Boer JG; Ushijima T; Nagao M; Glickman BW
    Mutat Res; 2000 Jul; 452(1):101-21. PubMed ID: 10894896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of cII gene mutation in the brains of Big Blue mice exposed to acrylamide and glycidamide in drinking water.
    Li HF; Shelton SD; Townsend TA; Mei N; Manjanatha MG
    J Toxicol Sci; 2016; 41(6):719-730. PubMed ID: 27853100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACB-PCR measurement of H-ras codon 61 CAA→CTA mutation provides an early indication of aristolochic acid I carcinogenic effect in tumor target tissues.
    Wang Y; Arlt VM; Roufosse CA; McKim KL; Myers MB; Phillips DH; Parsons BL
    Environ Mol Mutagen; 2012 Aug; 53(7):495-504. PubMed ID: 22729866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated microRNA, mRNA, and protein expression profiling reveals microRNA regulatory networks in rat kidney treated with a carcinogenic dose of aristolochic acid.
    Li Z; Qin T; Wang K; Hackenberg M; Yan J; Gao Y; Yu LR; Shi L; Su Z; Chen T
    BMC Genomics; 2015 May; 16(1):365. PubMed ID: 25952319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of mutagenic mode of action in Big Blue mice fed methylphenidate for 24 weeks.
    Manjanatha MG; Shelton SD; Dobrovolsky VN; Shaddock JG; McGarrity LG; Twaddle NW; Moore MM; Mattison DR; Slikker W; Morris SM
    Mutat Res; 2009; 680(1-2):43-8. PubMed ID: 19778631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.